AARHUS, Denmark — Scientists and researchers at Aarhus University Hospital in Denmark say they believe there will be a breakthrough in finding a cure for the human immunodeficiency virus (HIV) “within months.”
Researchers are testing a technique that involves releasing the HIV virus from “reservoirs” it forms inside DNA, bringing it to the surface of the cells. Once it comes to the surface, the body’s natural immune system can kill the virus through being boosted by a “vaccine.”
Get the Daily Brief
The news you care about, reported on by the people who care about you:
The Telegraph UK reported that the results of the trial tests, where the technique has already been proven to work in laboratory, now has shifted to human trials currently being conducted.
The results of the laboratory tests convinced the Danish Research Council to awarded 12 million Danish Kroner ($2.97 million) to carry out clinical trials on humans.
“I am almost certain that we will be successful in releasing the reservoirs of HIV. The challenge will be getting the patient’s immune system to recognize the virus and destroy it.
This depends on the strength and sensitivity of individual immune systems,” Dr. Ole Sogaard, a senior researcher at the Aarhus University Hospital in Denmark, said.
Sogaard also noted that 15 patients are currently taking part in the human trials, and if those patients respond to positively to the treatment the program will be expanded.
Sogaard cautioned that certain behaviors, such as unprotected sex and sharing needles, remained of paramount importance in the fight against HIV, and that a cure is not the same as a preventative vaccine.
According to the National Institutes For Health in Bethesda, Md., the current regime of medications and treatment make it possible for an HIV-positive patient to live a relatively normal life with few side effects even into old age, but if treatment is stopped then symptoms reappear within two weeks.
The Danish research team is utilizing powerful drugs called Histone deacetylase inhibitors (HDAC), which have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics and also as treatments for cancers and inflammatory diseases.
Article continues belowThe treatment potential was discovered almost by accident when Timothy Brown, an HIV sufferer developed leukemia.
Brown had a bone marrow transplant from a donor with a rare genetic mutation, which made his cells resistant to HIV. Brown, known as “the Berlin patient,” is believed to be the first man to ever be cured of the disease.
His case caused a revolution in research, with two new principal approaches. The first is gene therapy, which is expensive and not easily transferable to gene pools around the world, and aims to make a person’s immune system resistant to the HIV virus. The second being the HDAC inhibitor approach.
Worldwide the number of new infections in adults has become broadly stable for the past 4 years. In 2011, 0.77% of the world’s population or 34 million people were recorded as suffering from HIV, according to the World Health Organization (WHO).